Original Article

The Impact of Maternal Age on Chromosomal Aneuploidy, Blastocyst Quality, and Pregnancy Outcomes During Intracytoplasmic Sperm Injection Cycles

Aghajani Shahrzad[1], Salehzadeh Ali[1*], Ghasemian Fatemeh[2], Mehrafza Marzieh[3], Hosseini Ahmad[3]

1. Department of Biology, Rasht Branch Islamic Azad University, Rasht, Iran
2. Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran
3. Mehr Fertility Research Center, Guilan University of Medical Sciences, Rasht, Iran

Abstract

Background & Objective: Assisted reproduction techniques and preimplantation genetic testing (PGT) for aneuploidies help infertile couples achieve a healthy live birth. The objective of this study was to investigate if there is a correlation between chromosomal aneuploidy and maternal age.

Materials & Methods: We used 277 embryos with 6-8 cells and graded A derived from intracytoplasmic sperm injection cycles. There were two subgroups: fresh-PGT cycles (n = 38) and Frozen Embryo Transfer (FET) cycles (n = 38). The PGT cycles results were evaluated by fluorescence in situ hybridization and polymerase chain reaction assays. Couples (n = 76) with PGT on the third day were classified into four maternal age groups: ≤35 years (n = 35), 36-40 years (n = 24), 41-45 years (n = 11), and ≥46 years (n = 6). The rate of aneuploidy, blastocyst quality, and pregnancy was assessed in FET and fresh-PGT cycle.

Results: Aneuploidy rate in 13, 18, 21, X, and Y chromosomes in FET and fresh-PGT cycles are not significantly related to maternal age (p = 0.1). Significant differences were found in a decreased chemical pregnancy (p = 0.001), clinical pregnancy (p = 0.001), ongoing pregnancy (p = 0.001), and live birth rate (p = 0.001) among both groups. Decreased blastocyst rate increased maternal age in fresh PGT and FET PGT (p = 0.02). Early and clinical pregnancy loss was not related significantly to maternal age.

Conclusion: After evaluating cycle characteristics, an association was found between maternal age and declined pregnancy outcomes in embryos. There was a significant relationship between increasing female age with decreasing blastocyst rate.

**Keywords:** Blastocyst Quality, Pregnancy Outcomes, Intracytoplasmic Sperm Injection Cycles, Fluorescence in Situ Hybridization, Preimplantation Genetic Testing

Introduction

In modern society, postponing maternity has been rising continually. On the one hand, there were some educational, professional, economic, and personal reasons (1, 2). But, on the other hand, increasing aneuploidy rate with maternal age was the foremost hurdle to reproductive success (3, 4).

Maternal aneuploidy raises with female age, achieving up to 80% by 45 (4). Meiotic and primary mitotic errors may result in more rede of aneuploidy in higher maternal age. Embryonic early cleavage was affected by the oocyte attributes, whereas the 4-6 cell stage of embryo development was affected by both the sperm and the oocyte (5). The leading cause of the whole chromosomal aneuploidy in human embryos is meiotic errors.

*Corresponding Author: Salehzadeh Ali, Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran
Email: salehzadeh@iaurasht.ac.ir
https://orcid.org/0000-0003-4238-0999

Aghajani Shahrzad: https://orcid.org/0000-0001-7419-4213
Ghasemian Fatemeh: https://orcid.org/0000-0001-9284-6545
Mehrafza Marzieh: https://orcid.org/0000-0002-0476-6535
Hosseini Ahmad: https://orcid.org/0000-0003-1871-2957

They are the primary maternal sources and occur pending the complex stages of oogenesis. It is primarily via nondisjunction, which is the defeat of homologous chromosomes or sister chromatids to detached each other, and via unbalanced pre-division, leading to immature segregation and subsequent miss separation of sister chromatids (6, 7).

A strategy for improving intracytoplasmic sperm injection (ICSI) treatment outcomes due to identifying euploid embryos is to analyze the chromosome status of the embryo using preimplantation genetic testing for aneuploidy (PGT-A). Thus, it can be prioritized to transfer to the uterus. In addition, PGT-A may also be helpful for patients following the third-party reproduction with the contention of conceptional carriers to minimize the miscarriage rate and shorten the time to pregnancy among this population (8, 9).

The women aged more than 35-year experienced a demonstrative raise in embryo aneuploidy rate from a 30% baseline generation up to 90% in their late 40 before menopause (10). Specifically, the prospect of generating a chromosomally normal blastocyst could be even less than 5% in women aged more than 43 years (11). On the one hand, this can be ascribed to the slow discharge of the ovarian reserve. On the other hand, the progressive decrease in oocyte and embryo eligibility can be determined as the capability to generate a live birth (12, 13). Many different factors might also influence a woman's reproductive potential; hence, to rule them out, other investigations, including thyroid function, coagulation disorders, previous chlamydial infections, tubal patency, and sperm quality, are recommended. Complete consulting to experts is also axial. Covering any conceptional complexity, such as preeclampsia, diabetes, hypertension, placenta previa, placental abruption, intrauterine growth restriction, pre-term delivery, low birth weight, fetal deaths, and a higher occurrence of the obstetrical situation are also possible. The first step for a physician in reducing misinformation is to look upon pre-pregnancy educations (14).

Therefore, preimplantation genetic screening (PGT-A) of embryos is a widely used method for embryo selection and the possibility of gaining euploid blastocysts as a focus for clinicians' consulting. Factors include the number of oocytes, mature follicles, and female age (3, 15).

This study investigated the possible correlation between 13,18, 21, X, and Y chromosomal deviation and maternal age in embryos from frozen embryo transfer (FET) and fresh embryo transfer cycles. All results from the PGT-A procedure on day three single blastomere biopsy were obtained by fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) assays for 13,18, 21, X, and Y chromosomes. Finally, pregnancy and miscarriage results were evaluated.

Materials & Methods
Patients, study design, and study groups

This observational study was conducted at Mehr Fertility Center, Rasht, Iran, for about two years, from February 2018 to January 2020. This study was approved by the Research Ethics Board of Islamic Azad University, Rasht Branch (Ethics approval code no.1398.053).

All women underwent a comprehensive fertility workup, including a detailed medical history, laboratory evaluation, and pelvic ultrasound before initiating the treatment. They also underwent an assessment before ICSI, including medical history, laboratory evaluation, and male semen analysis. The study analysis included infertility patients undergoing ICSI cycles involved in PGT-A in the fresh and frozen embryo transfer cycles. After centrifugation, this study used a standard swim-up technique to prepare all semen samples to determine a possible contribution to the sperm preparation method on embryo aneuploidy. Furthermore, the patients who underwent the ICSI cycle and requested PGT without embryos with 6-8 cells and grade A were excluded from the research process. A total of 277 embryos with 6-8 cells and grade A, derived from ICSI with single blastomere biopsy were combined with comprehensive chromosome screening using fluorescence in situ hybridization (FISH) and the polymerase chain reaction (PCR) methods 13, 18, 21, X, and Y chromosomes were performed. Subsequently, 1 to 3 euploid embryos were transferred.

Patients aged from 21 to 47 years old for females. There were two subgroups in terms of type of cycle insist of Fresh PGT (n = 38) and PGT (n = 38) and then the patients were allocated into four maternal age groups: ≥35 years (n = 35); 36-40 years (n = 24); 41-45 years (n = 11); 46≥ years (n = 6). Patients ′ clinical charts obtained demographic and clinical data, including paternal and maternal age, initial semen parameters (pre-wash), oocyte count, embryo count and quality, and PGT-A results. As a result of the natural difference of male age among the study groups, the researcher, depending on male age in the results, assessed male age and semen quality in each group to avoid the entrance of any compounding agent. The primary outcome measures were aneuploidy, euploidy, and blastocyst formation rates. Secondary endpoints compared chromosome aneuploidy and analyzed the overall percentage of pregnancy outcome and losses in each group. Then, the results were evaluated in terms of human embryos' developmental potential in each group using the Gardner method (16). All applicants were informed about the procedure's success rate, the cost, the probability of not finding the healthy embryo, and the possibility of not observing the desired signals from the embryos.

Ovarian Stimulation and embryo culture

Ovarian stimulation for ICSI included a standard agonist-based protocol (17). The dosing regimen chosen by each physician was according to the pre-stimulation assessment of parameters, including anti-Mullerian hormone, antral follicle count, and prior stimulation cycle response. Oocyte collection was performed approximately 36 hours post-triggering. After ovum pick-up, mature (metaphase II) oocytes were fertilized by intracytoplasmic sperm injection (ICSI). Following ICSI, all fertilized oocytes were cultured individually from day one to day five in 25 mL droplets of a single culture medium with a serum protein supplement (Life Global) under oil. On day three, laser-assisted embryo biopsy was performed in the total global medium (Life Global) under oil. Embryos were evaluated on days three and five with the Gardner method (16).

Embryo culture and evaluation

The cultured embryos were evaluated on the third day after ICSI. Based on Gardner's Method, the embryos were classified into three groups; group A (6 to 8 blastomeres with the exact size and ≤ 10% fragmentation rate), group B (6-8 blastomeres with even or non-even size, and 10% to 20% fragmentation rate), and group C (low number and uneven blastomeres with more than 20% fragmentation). On day five, the blastocysts were scored based on the Gardner Method, which explains the extent of blastocoel expansion and establishment of trophectoderm (TE) and inner cell mass (ICM) development.

The rating of re-expansion was determined as follows: 1 = early blastocyst; cavity started to the formation, 2 = early blastocyst; cavity was less than 50% of the total embryo, 3 = full blastocyst; cavity thoroughly loaded with the embryo, 4 = expanded blastocyst; cavity volume became bigger than complete blastocyst, zona pellucida slimming, 5 = hatching blastocyst; TE was herniating via the zona, 6 = hatched blastocyst; blastocyst completely exited from the zona. ICM was graded as follows: A = many cells; firmly compacted, B = some cells; firmly compacted, C = some cells; disordered, D = few cells; disordered. The TE grading was defined as follows: A = forming a coherent epithelium in many cells, B = moderate cells making a weak epithelium, C = some cells making a weak epithelium, D = very few cells (16). Considering the accurate time of oocyte retrieval on day 0, all scored blastocyst were taken on the morning of day five.

Vitrification-thawing technique

On the day of hCG administration, the embryo transfers of patients with homogenous hyperechogenic endometrium and serum progesterone levels greater than two ng/mL were canceled. Embryos with grade A were vitrified on day three for subsequent cycles as a FET-PGT cycle. The vitrification and warming procedures were conducted according to the recommended protocol in Kitazato Vitrification Kit. In brief, the embryos were then placed in vitrification solutions in two steps for 15 minutes and 40-50 seconds.

First, embryos were picked up into the tip of a transfer pipette using a minimal volume of vitrification solution (0.1 μL or less) and then placed on a Cryotop strip. Then, the strip with the embryos was plunged into liquid nitrogen. For thawing, the frozen embryos were immediately immersed in a 37 °C warming solution for 1 minute. They were then recovered and rehydrated using a 3-step dilution protocol at room temperature. Finally, the embryos were transferred to embryo culture media (16).

Evaluation of embryos after warming

The embryos were thawed, and then their quality was determined by quantifying the proportion of morphologically intact cells in the embryo. Embryos were considered intact when all blastomeres had well-defined membranes and cytoplasm with no sign of degeneration. In this study, embryos were incubated for an additional two-day to assess blastulation potential. The embryos were then cultured in embryo medium (Global total, COOPER) covered by oil in a 37°C incubator (SANYO, MCO-5AC) with a 6% CO_2, 5% O_2, and 89% N_2 atmosphere to the blastocyst stage. Based on the degree of expansion and hatching status, blastocysts were given numeric scores from 1–6 (16).

Embryo biopsy and PGT procedure

A single blastomere biopsy was accomplished on the third day based on morphologic evaluation and hatching rate (18). Firstly, cleavage stage embryos (day three) were transferred into a cation (Na^+ and Mg^{++}) free medium. Then zona pellucid was hatched locally; so that just a single blastomere could be removed. The blastomere was then gently aspirated using an appropriate biopsy microneedle, and then the blastomere was removed from the embryos and remained biopsied embryos. The blastomeres were considered by the FISH technique (19). All biopsy samples were in hypotonic wash buffer and deferred for analysis, and all embryos were cultured again after the biopsy. PGT results were described as euploid or aneuploid established on the FISH method and PCR platform. Embryos with available PGT-A results were classified as euploid or aneuploid.

Embryo selection for transfer

Euploid blastocyst embryos with the expansion grades 2, 3, 4, and 5 were selected to be transferred. The embryo grade on day five was considered for embryo selection among the biopsied embryos by evaluating expansion, TE, and ICM morphology (20). FET was performed after the synthetic preparation of the endometrium. Embryo thawing and transfer were performed after five days of progesterone supplementation. Embryo transfer was performed with a Cook catheter under abdominal ultrasound guidance on day five.

Outcome measures

Chemical pregnancy, clinical pregnancy, ongoing pregnancy, and live birth were considered as the primary outcomes. Chemical pregnancy was confirmed by a positive βhCG test 14 days after the embryo transfer. The sonographic evidence of fetal heartbeat confirmed clinical pregnancy. Ongoing pregnancy was defined as a viable intrauterine gestation at the time of discharge from the practice, which occurred not earlier than eight weeks of gestation. Live birth was considered as the delivery of a live-born infant after 28 weeks gestation. The secondary outcomes included the clinical pregnancy rate, early pregnancy loss (EPL) rate, and clinical pregnancy loss (CPL) rate. EPL was defined as a pregnancy loss occurring before the detection of an intrauterine gestational sac on ultrasound. CPL was described as a loss following the detection of the fetal heartbeat on an ultrasound.

Statistical Analysis

Distribution and the normality of cycle characteristics were evaluated using the Kolmogorov-Smirnov test. Continuing variables were expressed as mean with SD if normally distributed and median with interquartile range (IQR), if not normally distributed.

Categorical variables were expressed as frequencies with percentages. Continuing variables were compared between age groups using analysis of variance if normally distributed, or Kruskal-Wallis, if not normally distributed. Chi-square or Fisher's exact test was used whenever proper to compare categorical data. Due to multiple patients (n = 76) providing multiple eggs (n = 1,093) in our data set, we performed a generalized linear mixed model to account for embryo-level variability for outcomes of aneuploidy and euploidy. Maternal and paternal age groups, semen volume, semen concentration, semen motility,oocyte count, and quality were considered fixed effects, whereas patients were considered a random effect. Nelder-Mead optimization was used to determine parameter estimates.

Continuing variables were scaled for regression analysis. Output beta-coefficients and 95% confidence intervals (CIs) limits exponentiated to raw odds ratios and corresponding 95% CIs for clinical interpretability. Statistical analysis was done using SPSS version 23. $P < 0.05$ was considered statistically significant.

Results

The study included 1093 oocytes from women aged 21–47 undergoing ICSI antagonist cycles, in which PGT-A was performed. Thus, a total of 277 embryos from 76 patients met the inclusion criteria. After excluding no detected embryos 62/277(22.38%), a total of 215 embryos were included in the final analysis (Figure 1).

Figure1. In-situ hybridization with X, Y, 13,18, and 21 chromosome-specific DNA probs. X-specific prob is shown labelled in blue, chromosome Y in green, chromosome 13 in orange, chromosome 18 in Purple, and chromosome 21 in red. (a) normal male blastomere (X, Y, 13, 13, 18, 18, 21, 21); (b) trisomy 13 female blastomere (X, X, 13, 13, 13, 18, 18, 21, 21); (c) normal female blastomere (X, Y, 13, 13, 18, 18, 21, 21); trisomy 21 female blastomere (X, X, 13, 13, 18, 18, 21, 21, 21)

There were 153/215 (71.16%) euploid embryos and 62 (28.84%) aneuploid in the 13, 18, 21, X, and Y chromosomes in embryos with the detected signal. According to maternal age distribution, no clear correlation was found between embryo aneuploidy rates (p = 0.1). Therefore, the age range groupings were used for the detailed analysis.

Patients were allocated into four maternal age groups: ≥35 years (n = 35); 36-40 years (n = 24); 41-45 years (n = 11); 46≥ years (n = 6). A detailed comparison of baseline cycle characteristics among the study groups is presented in Table 1. There was no significant difference in affective cycle characteristics among the study groups.

Table 1. Comparison of ICSI cycle characteristics for 76 patients. Male age (p = 0.001, 0.023), number of oocytes retrieved (p = 0.001) and number of matured oocytes (p = 0.001) was significant

Type of cycle	Freeze cycle PGT (n = 38)					Fresh cycle PGT (n = 38)				
Female age groups	<=35	36-40	41-45	>=46	p-value	<=35	36-40	41-45	>=46	p-value
	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD		Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	
Male age (years)	40.38± 4.46	41.63± 4.49	48.53± 3.38	48.20± .77	0.001	39.97± 9.67	41.93± 4.35	42.57± 3.69	52.00± 0.00	0.023
Count of semen (million)	30.5 ± 14.11	32.6 ± 17.45	26.2 ± 23.02	23.2 ± 13.12	NS	24.3 ± 18.91	30.6 ± 23.33	27.3 ± 20.10	20.00± 0.00	NS
Motility of semen (%)	55.7 ± 22.15	55.5 ± 25.64	49.8 ± 31.99	48.7 ± 13.12	NS	56.2 ± 17.01	58.2 ± 12.91	60.9 ± 25.50	50.00± 0.00	NS
Morphology of semen (%)	10.93± 4.70	9.54 ± 5.76	6.67 ± 7.24	11.60± 1.40	NS	8.58 ± 3.67	11.13± 3.92	10.71± 7.73	8.00 ±0.00	NS
Oocytes retrieved (n)	18.33± 6.20	24.0 ± 22.71	10.80± 7.19	9.07 ± 1.75	.001	14.29± 5.69	10.80± 3.15	11.21± 2.83	16.00±0.00	0.001
Matured oocytes (n)	15.58± 4.86	19.2 ± 17.47	10.27± 6.70	8.00 ± 1.60	.001	12.05 ± 5.12	9.46 ± 2.68	9.43 ± 2.50	16.00 ±0.00	0.001
Cleavage embryo (n)	9.99 ± 4.13	12.8 ± 10.10	7.47 ± 4.67	8.00 ± 1.73	NS	8.50 ± 3.78	8.28 ± 2.12	7.71 ± 3.24	10.00 ± 0.00	NS
Transferred embryo (n)	1.61 ± .70	1.86 ± .69	2.00 ± .82	1.33 ± .58	NS	1.64 ± .67	1.73 ± .79	1.33 ± .58	1.00 ± 0.00	NS
Biopsy embryo (n)	5.70 ± 2.11	5.33 ± 2.92	4.20 ± 2.68	5.25 ± 2.75	NS	5.20 ± 2.61	5.38 ± 2.36	4.50 ± 2.38	5.00 ±0.00	NS

Note: data are presented as mean ±standard deviation; P<0.05, t-test or Fisher's test, as appropriate

The rate of aneuploidy in 13, 18, 21, X, and Y chromosomes, embryo development in FET, and fresh cycle are not significantly related to maternal age (p = 0.1) (Table 2). There was a significant difference in the blastocyst rate among maternal age groups (P-value 0.002).

Significant differences among maternal age groups were found in Chemical pregnancy (p = 0.001), Clinical pregnancy (p = 0.001), Ongoing pregnancy (p = 0.001), and Life birth rate (p = 0.001) (Chart 1).

Chart 1. Pregnancy outcome in four maternal age groups: There is a significant difference in decreasing pregnancy results in both groups (Chemical pregnancy, Clinical pregnancy, Ongoing Pregnancy, and Life birth rate (p-value: <0.001))

There was no significant relationship between maternal age and EPL and CPL (p = 0.08). There was also no significant difference between embryo development in FET and fresh cycle with maternal age.

Generalized analysis at the embryo level showed that oocytes retrieved (p = 0.001) and matured oocytes (p = 0.001) were significantly associated with female age (Table 2).

Table 2. Developmental and pregnancy outcomes concerning maternal age. Decreasing blastocyst rate (p = 0.002) and pregnancy outcomes (p = 0.001) was significant.

Variables	Maternal age range (%) (years)				
Age range	≥35	36-40	41-45	46≥	p-Value
Aneuploidy rate	24.2%	20.8%	27.8%	33.3%	NS
Blastocyst rate	38.8%	25.0%	9.4%	38.8%	0.002
Euploid blastocyst rate	76.0%	80.0%	0.0%	50.0%	NS
Chemical pregnancy	54.4%	33.3%	37.5%	67.3%	0.001

Clinical pregnancy	40.3%	25.0%	6.3%	67.3%	0.001
Ongoing pregnancy	40.3%	20.8%	6.3%	67.3%	0.001
Life birth rate	36.9%	20.8%	6.3%	53.1%	0.001

There was a significant relation among Clinical pregnancy (p = 0.01), Ongoing pregnancy (p = 0.01), and Life birth rate (p = 0.01) especially in 41-45 age female group in the fresh cycle. For influential maternal factors, male and female age, oocyte count, semen concentration, semen motility, and semen morphology were significantly associated with aneuploidy rate, blastocyst rate, and pregnancy outcomes (Table 3).

Table 3. Developmental and pregnancy outcomes related to maternal age, oocyte count (Mean no ± SD, P-value), chemical pregnancy in FET cycles with PGT and clinical pregnancy, ongoing pregnancy, and live birth rate in Fresh cycles with PGT was significant due to female age

			Aneuploidy rate	Blastocyst rate	Chemical pregnancy	Clinical pregnancy	Ongoing pregnancy	Live birth rate
FET Cycle With PGT (n=38	Female age	Mean ± SD	34.96±5.31	36.30±5.22	36.38±5.30	36.34±5.61	35.91±5.78	36.67±6.29
		p-value	NS	NS	0.04	NS	NS	NS
	Oocyte count	Mean ± SD	15.80±6.39	11.75±7.14	13.36±5.81	14.86±3.98	15.67±3.67	15.80±4.09
		p-value	NS	NS	0.017	NS	NS	NS
Fresh Cycle With PGT (n=38)	Female age	Mean ± SD	35.35±5.21	32.60±4.19	35.33±5.07	36.21±4.66	36.21±4.66	36.21±4.66
		p-value	NS	0.001	NS	NS	NS	NS
	Oocyte count	Mean ± SD	9.25±3.59	10.60±5.40	10.11±4.73	8.43±33.69	8.43±33.69	8.43±33.69
		p-value	NS	NS	NS	0.011	0.011	0.011

*P<0.05, t-test or Fisher's test exact test, as appropriate. NS = not statistically significant

The odds ratio of pregnancy outcomes based on composite expansion grade and maternal age were analyzed compared to expansion five embryos. Achieving expansion grade 3 was significantly higher in group A compared with other groups with referencing expansion 5 embryos (odds ratio = 1.38(0.33-5.78) vs 0.38 (0.08-1.77), 0.76 (0.05-10.48), and 0.57 (0.07-4.55)); and in expansion 5 group B vas pioneer (odds ratio = 1.53(0.13-17.33) vs references)

Table 4. Odds of pregnancy outcomes based on composite expansion grade and maternal age compared with expansion five embryos. Expansion 3 in ≥35 groups and expansion 5 in 36–the 40-year-old group had more OR

	OR (99% CI)	OR (99% CI)	OR (99% CI)	OR (99% CI)
Age range	≥35	36-40	41-45	46≥
Expansion grade				
3	1.38(0.33-5.78)	0.38(0.08-1.77)	0.76(0.05-10.48)	0.57(0.07-4.55)
4	0.68(0.20-2.33)	0.15(0.02-1.06)	Zero sample size	0.86(0.18-4.14)
5	Reference	1.53(0.13-17.33)	Small sample size	Small sample size
*Note: CI = confidence interval; OR = odds ratio;				

Discussion

By developing techniques used for PGT, chromosome aneuploidy could be tested in the embryos in a preimplantation stage. However, to date, the contribution of maternal age to embryo aneuploidy, developmental potential, and pregnancy outcomes remains uncertain.

In this study, the data showed no relationship between maternal age and aneuploidy rate (determined using FISH and PCR assays for PGT-A) in 277 embryos derived from ICSI patients. In addition, the researchers observed a significant relationship between blastocyst rate and pregnancy outcomes. The results of this research are consistent with some previous studies, including the one recently published by Gonzalez et al. (21). They analyzed an outsized cohort of 1,549 embryos from IVF clinics using Next-Generation Sequencing (NGS) technology. Their results showed that maternal age does not have an impact on the prevalence of embryo aneuploidy. However, the aneuploidy rate they reported ranged is different from our result. It could be explained by differences in used technology, treatment protocols among centers, IVF culturing conditions, or interpretation of PGT-A results to include a report (22).

Given that aneuploidy rates often suffer from confounding factors, such as semen parameters, ovum donor, and cycle parameters (23, 24), we have included these factors in the statistical analysis with proper adjustments to control their effects. So far, no other study has used detailed clinical data on the oocytes and sperm parameters and ICSI cycle characteristics to regulate their effects on the results parameter rate.

Further supporting our findings, some studies using genotyping technology to determine the maternal origin of aneuploidy also reported no correlation between maternal age and aneuploidy (3, 24). For example, in their study, using single nucleotide polymorphism (SNP) array technology, Sills et al. (3) reported that there is no correlation between maternal age and embryo aneuploidy, McCoy et al. (24).

This study indicated that the frequency of aneuploidy in chromosomes would not increase significantly with maternal age. But the rate of embryos achieving blastocyst stage with expansion 3, 4, and 5 and pregnancy outcomes decreased significantly with parental age.

Aneuploidy was mainly higher in the older ages due to meiosis errors during the development of oocytes. Demco et al., in their study, found that there is an inverse relationship between maternal age and euploid embryos (3). This study showed that the average clinical pregnancy rate is 30.92%, and the live birth rate is 25.8%. As a result, based on age, pregnancy outcomes were statistically significant.

Evaluating maternal age and type of FET or fresh cycle by fluorescent in situ hybridization technology (FISH) and PCR assays on chromosomes is this research's strength. The data were collected from one fertility center. Another emphasis of the study since all genetic analyses, embryo culture, and ovarian stimulation was operated at a single center, thus obliterating significant genetic analysis variation, embryo handling, and clinical protocols as confusing factors. Furthermore, to support the study results, standardized methods of semen analysis and oocyte screening were used. As another merit of this study, multiple regression analyses were conducted to analyze potential confounding effects from oocyte and sperm parameters and cycle characteristics.

The main limitation of this study was that the used genetic analysis technology was an old technology for genetic diagnosis. To have more effective and complete evaluations, whole-genome assessment methods are more appropriate. Interestingly, newer genotyping assays like SNP-NGS sequencing are emerging, which could allow us, within the future, to rise and characterize the origin of aneuploidy in embryos. Besides this, the older maternal age results should be interpreted with caution due to the smaller sample size of the group.

Conclusion

In the present study, the researchers found that after adjusting the semen quality, oocyte information, and ICSI cycle characteristics, there is a significant relationship between maternal age with pregnancy outcomes and blastocyst rates in embryos derived from ICSI cycles. Thus, our data add to the general knowledge of maternal age's effect on human embryo aneuploidy and developmental potential. In addition, our findings may assist in providing presentational consulting to older women who wish to have children.

Acknowledgement

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Saumet J, Petropanagos A, Buzaglo K, McMahon E, Warraich G, Mahutte N. 356-egg is freezing for age-related fertility decline. Journal of Obstetrics and Gynaecology Canada. 2018;40(3):356-368.

2. Gunnala V, Schattman G. Oocyte vitrification for elective fertility preservation: the past, present, and future. Current Opinion in Obstetrics and Gynecology. 2017;29(1):59-63.

3. Demko ZP, Simon AL, McCoy RC, Petrov DA, Rabinowitz M. Effects of maternal age on euploidy rates in a large cohort of embryos analyzed with 24-chromosome single-nucleotide polymorphism–based preimplantation genetic screening. Fertility and sterility. 2016;105(5):1307-1313.

4. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertility and sterility. 2014;101(3):656-663.

5. McCallie B. Biological Mechanisms Impacting Pre-Implantation Embryo Development: (Ph.D. Thesis). The University of Kent. 2021;40-51.

6. Tšuiko O, Jatsenko T, Grace LKP, Kurg A, Vermeesch JR, Lanner F, et al. A speculative outlook on embryonic aneuploidy: Can molecular pathways be involved? Developmental biology. 2019;447(1):3-13.

7. Gruhn JR, Zielinska AP, Shukla V, Blanshard R, Capalbo A, Cimadomo D, et al. Chromosome errors in human eggs shape natural fertility over reproductive life span. Science. 2019;365(6460):1466-1469.

8. Sacchi L, Albani E, Cesana A, Smeraldi A, Parini V, Fabiani M,

et al. Preimplantation Genetic Testing for Aneuploidy Improves Clinical, Gestational, and Neonatal Outcomes in Advanced Maternal Age Patients Without Compromising Cumulative Live-Birth Rate. Journal of assisted reproduction and genetics. 2019;36(12):2493-2504.

9.Neal SA, Morin SJ, Franasiak JM, Goodman LR, Juneau CR, Forman EJ, et al. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage. Fertility and sterility. 2018;110(5):896-904.

10.Capalbo A, Hoffmann ER, Cimadomo D, Maria Ubaldi F, Rienzi L. Human female meiosis revised: new insights into the mechanisms of chromosome segregation and aneuploidies from advanced genomics and time-lapse imaging. Human Reproduction Update. 2017;23(6):706-722.

11.Ubaldi FM, Cimadomo D, Capalbo A, Vaiarelli A, Buffo L, Trabucco E, et al. Preimplantation genetic diagnosis for aneuploidy testing in women older than 44 years: a multicenter experience. Fertility and sterility. 2017;107(5):1173-1180.

12.Keefe D, Kumar M, Kalmbach K. Oocyte competency is the key to embryo potential. Fertility and Sterility. 2015;103(2):317-322.

13.Cimadomo D, Fabozzi G, Vaiarelli A, Ubaldi N, Ubaldi FM, Rienzi L. Impact of maternal age on oocyte and embryo competence. Frontiers in endocrinology. 2018,;9:327-333.

14.Ubaldi FM, Cimadomo D, Vaiarelli A, Fabozzi G, Venturella R, Maggiulli R, et al. Advanced maternal age in IVF: still a challenge? The present and the future of its treatment. Frontiers in endocrinology. 2019;10:94-99.

15.Zheng Z, Zhao X, Xu B, Yao N. What should we focus on before preimplantation genetic diagnosis/screening? Archives of medical science: AMS. 2018;14(5):1119.

16.Gardner DK, Weissman A, Howles CM, Shoham Z. Textbook of Assisted Reproductive Techniques: Volume 2: Clinical Perspectives: CRC Press; 2017;5:720-738.

17.Song D, Shi Y, Zhong Y, Meng Q, Hou S, Li H. Efficiency of mild ovarian stimulation with clomiphene on poor ovarian responders during IVF\ICSI procedures: a meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016;204:36-43.

18.Sawarkar S, Munné S. Current and Novel Methods for Chromosome Testing. In Vitro Fertilization: Springer; 2019;p. 603-612.

19.Group EP-SP-AW, Coonen E, Rubio C, Christopikou D, Dimitriadou E, Gontar J, et al. ESHRE PGT Consortium good practice recommendations for the detection of structural and numerical chromosomal aberrations. Human Reproduction Open. 2020;3:1-7.

20.Nazem TG, Sekhon L, Lee JA, Overbey J, Pan S, Duke M, et al. The correlation between morphology and implantation of euploid human blastocysts. Reproductive biomedicine online. 2019;38(2):169-176.

21.Lee C-I, Wu C-H, Pai Y-P, Chang Y-J, Chen C-I, Lee T-H, et al. Performance of preimplantation genetic testing for aneuploidy in IVF cycles for patients with advanced maternal age, repeat implantation failure, and idiopathic recurrent miscarriage. Taiwanese Journal of Obstetrics and Gynecology. 2019;58(2):239-243.

22.Jiang S, Peng X, Gong F, Huang C, Peng Y, Long X, et al. The role of total chromosomal disomy in human spermatozoa as a predictor of the outcome of preimplantation genetic screening. Fertility and sterility. 2020;113(6):1196-1204.

23.La Marca A, Minasi MG, Sighinolfi G, Greco P, Argento C, Grisendi V, et al. Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertility and sterility. 2017;108(5):777-783.

24.McCoy RC, Demko ZP, Ryan A, Banjevic M, Hill M, Sigurjonsson S, et al. evidence of selection against complex mitotic-origin aneuploidy during preimplantation development. PLoS Genet. 2015;11(10):100-156.